Creative Touch Permanent Makeup and Aesthetics

Beta-oxidation is the primary pathway by which the body extracts energy from fat: a stepwise, cyclic process in the mitochondrial matrix that removes two-carbon acetyl-CoA units from fatty acyl- CoA chains, producing one NADH and one FADH₂ per cycle as reducing equivalents for the electron transport chain. It operates downstream of CPT-1 – which controls mitochondrial entry – and upstream of the TCA cycle, where its acetyl-CoA output is fed to produce ATP. The accumulation of acetyl-CoA and NADH that beta-oxidation generates is precisely the signal that inactivates the pyruvate dehydrogenase complex and suppresses glucose oxidation, completing the Randle Cycle’s fat-burns-glucose-is-suppressed direction. In skin, PPAR-alpha – the primary transcriptional regulator of beta-oxidation genes – additionally governs keratinocyte differentiation, lamellar body formation, and barrier lipid secretion, connecting fat-burning capacity to epidermal structural function. ^[8]

Beta-oxidation is the metabolic pathway through which long-chain fatty acids, once transported into the mitochondrial matrix by the carnitine shuttle, are progressively disassembled into two-carbon acetyl-CoA units through a repeating cycle of four enzymatic reactions. Each complete cycle shortens the fatty acyl chain by two carbons, releasing one acetyl-CoA molecule alongside one NADH and one FADH₂ – reducing equivalents that enter the electron transport chain to drive ATP synthesis. A 16-carbon fatty acid requires seven cycles to fully dismantle, yielding eight acetyl-CoA, seven NADH, and seven FADH₂. The pathway is not simply a fuel-burning process: the metabolic signals it generates – rising acetyl-CoA/CoA and NADH/NAD⁺ ratios – actively suppress glucose oxidation at the pyruvate dehydrogenase complex, making beta-oxidation the upstream driver of the Randle Cycle’s most clinically relevant arm. ^[9]

The Four-Step Cycle

All four reactions occur in the mitochondrial matrix, acting on the acyl-CoA ester form of the fatty acid (produced by ACSL activation in the cytosol and transported by CPT-1): ^[3]

1. Oxidation (dehydrogenation): An acyl-CoA dehydrogenase removes two hydrogen atoms from the α and β carbons of the acyl chain, introducing a trans double bond between C2 and C3 (forming trans-Δ²-enoyl-CoA) and reducing FAD to FADH₂. The FADH₂ produced here enters the electron transport chain at ubiquinone (complex II level), yielding approximately 1.5 ATP per molecule. The acyl-CoA dehydrogenases are chain-length specific – this matters both enzymatically and clinically, as discussed below.

2. Hydration: Enoyl-CoA hydratase adds a water molecule across the double bond, producing L-3-hydroxyacyl-CoA (also termed L-β-hydroxyacyl-CoA). This hydroxyl group at the β-carbon is the defining structural feature from which the pathway takes its name.

3. Oxidation: L-3-hydroxyacyl-CoA dehydrogenase oxidises the β-hydroxyl group to a carbonyl (keto) group, producing 3-ketoacyl-CoA and reducing NAD⁺ to NADH. The NADH produced enters the electron transport chain at complex I, yielding approximately 2.5 ATP per molecule.

4. Thiolysis: β-ketothiolase (thiolase) cleaves the C2–C3 bond using a free CoA molecule, releasing acetyl-CoA and producing a new acyl-CoA that is two carbons shorter than the starting material. This shortened acyl-CoA re-enters the cycle at step 1, whilst acetyl-CoA proceeds to the TCA cycle.

The cycle repeats until the fatty acid is fully dismantled. For even-chain saturated fatty acids – the majority of dietary and endogenously produced fatty acids – the final cycle produces two acetyl-CoA molecules. For odd-chain fatty acids (less common, found in ruminant dairy fat and certain fish), the terminal product is one propionyl-CoA (three carbons), which is converted to succinyl-CoA via the methylmalonyl-CoA pathway – a conversion requiring vitamin B12 and biotin – and enters the TCA cycle via anaplerosis. ^[8]

Chain Length and Enzyme Specificity

The step 1 acyl-CoA dehydrogenases are chain-length specific, and the appropriate enzyme must be expressed for the cell to oxidise fatty acids of each chain length efficiently: ^[9]

MCAD deficiency deserves specific acknowledgement as the most common inherited disorder of fatty acid oxidation, occurring in approximately 1 in 10,000–17,000 births in northern European populations. Because MCAD is required to oxidise medium-chain acyl-CoAs – the products of partial VLCAD and LCAD activity – its absence creates a metabolic block precisely at the chain length range produced by proceeding cycles. During fasting or illness, when fat oxidation is the primary fuel source and glucose availability is low, MCAD-deficient individuals cannot sustain the pathway and develop hypoketotic hypoglycaemia – low glucose without the ketone body production that would normally compensate. This is a medical condition managed by avoiding prolonged fasting and is mentioned here for knowledge base completeness and contrast with the metabolic flexibility context in which beta-oxidation is otherwise discussed. ^[9]

Energetics: Why Fat Burns Longer

The ATP yield from fatty acid oxidation substantially exceeds that from glucose per carbon oxidised, which is why fat functions as the body’s long-term energy storage medium rather than as an immediate fuel reserve.

Full oxidation of palmitate (C16:0) produces: 8 acetyl-CoA → 80 ATP (from TCA cycle, approximately 10 ATP per acetyl-CoA) + 7 FADH₂ → 10.5 ATP + 7 NADH → 17.5 ATP = 108 ATP gross, minus 2 ATP equivalent for initial activation = approximately 106 net ATP. For comparison, complete glucose oxidation yields approximately 32 ATP. Per carbon atom: palmitate yields approximately 6.6 ATP per carbon versus approximately 5.3 ATP per carbon for glucose – fat delivers roughly 25% more ATP per carbon oxidised.

This energy density advantage comes with a cost: fat oxidation is oxygen-intensive. Palmitate combustion requires 23 molecules of O₂, whilst glucose combustion requires only 6 O₂. The respiratory quotient (RQ) reflects this – the ratio of CO₂ produced to O₂ consumed is 0.70 for fat versus 1.00 for glucose. A fasted individual breathing at RQ 0.70 is relying predominantly on fat oxidation; a fed individual at RQ approaching 1.00 is relying predominantly on glucose. The RQ shift from fasted to fed state – which should move from approximately 0.70 toward 0.85–1.00 after a carbohydrate-containing meal – is the physiological measurement of metabolic flexibility described in the Randle Cycle entity. A blunted shift (RQ remaining low in the fed state, or failing to fall adequately in the fasted state) is the measurable signature of metabolic inflexibility. ^[4]

Clinical Pearl Fat is not simply a “slow fuel” – it is a high-yield, oxygen-intensive fuel that the body reserves for sustained moderate-intensity energy demands: overnight fasting, sustained aerobic activity, and the baseline metabolic needs of cardiac muscle, which derives approximately 70% of its ATP from fatty acid oxidation at rest. Impairing beta-oxidation – through CPT-1 inhibition by elevated malonyl-CoA, or through VLCAD/MCAD insufficiency – forces a shift to less efficient glucose-based fuelling for these sustained demands.

Peroxisomal Beta-Oxidation: The Very Long-Chain Route

Mitochondrial beta-oxidation cannot efficiently handle very long-chain fatty acids (VLCFAs) of 22 carbons or longer. These substrates require a parallel pathway: peroxisomal beta-oxidation, which shares the four-step chemical logic but uses distinct enzymes, a different electron acceptor, and does not go to completion. ^[1]

Key distinctions from mitochondrial beta-oxidation: the first step uses acyl-CoA oxidase rather than an acyl-CoA dehydrogenase – producing H₂O₂ instead of FADH₂ (which is immediately neutralised by catalase, rather than entering the electron transport chain). The pathway proceeds only to octanoyl-CoA (C8), at which point the medium-chain product exits the peroxisome and transfers to mitochondria for the remaining beta-oxidation cycles. Peroxisomal oxidation therefore does not independently generate ATP from VLCFAs to completion; it processes them to a chain length that mitochondria can handle, with the ATP generation occurring in the mitochondrial phase. ^[1]

Entry of VLCFAs into peroxisomes requires the ABCD1 transporter (adrenoleukodystrophy protein, ALDP) on the peroxisomal membrane. Mutations in ABCD1 cause X-linked adrenoleukodystrophy (X-ALD), an inherited peroxisomal disorder in which VLCFAs accumulate in tissues – particularly the adrenal gland and white matter of the brain – producing adrenal insufficiency and progressive neurological demyelination. Skin fibroblasts are standard research models for peroxisomal VLCFA oxidation precisely because they express the complete complement of peroxisomal and mitochondrial beta-oxidation enzymes; VLCFA accumulation can be measured in fibroblast cultures from ABCD1 mutation carriers before clinical symptoms arise. ^[5]

An important interdependence has been documented: impaired mitochondrial long-chain beta-oxidation (including CPT-1 deficiency) reduces peroxisomal VLCFA beta-oxidation activity in fibroblasts, suggesting that the two systems are functionally coupled rather than operating as fully independent parallel pathways. ^[6]

Completing the Randle Cycle: The Acetyl-CoA/NADH Signal

Beta-oxidation generates the two metabolites that directly inhibit the pyruvate dehydrogenase complex and suppress glucose oxidation – completing the mechanistic loop described across the Randle Cycle, Acetyl-CoA, and PDH Complex entities.

Acetyl-CoA accumulates in the mitochondrial matrix as each beta-oxidation cycle releases it. When acetyl-CoA exceeds the TCA cycle’s capacity to consume it (i.e., when oxaloacetate availability is limiting, or when TCA cycle flux is already high), the acetyl-CoA/CoA ratio rises. This rising ratio activates PDK2 and PDK4, which phosphorylate E1α of the PDH complex and inactivate it. Glucose-derived pyruvate can no longer commit to acetyl-CoA; it accumulates or is diverted to lactate. ^[4]

NADH accumulates in parallel. Each beta-oxidation cycle produces one NADH, and the TCA cycle – which oxidises the released acetyl-CoA – produces a further three NADH per turn. When beta-oxidation is active and the TCA cycle is running at full capacity, the NADH/NAD⁺ ratio rises substantially in the mitochondrial matrix. PDH is directly and independently inhibited by high NADH/NAD⁺, providing a second, parallel mechanism of glucose suppression. ^[4]

These two signals – rising acetyl-CoA/CoA and rising NADH/NAD⁺ – do not operate sequentially; they operate simultaneously and reinforce each other’s inhibition of PDH. Together, they reduce glucose oxidation at the committed step with the greatest efficiency: even if glucose enters the cell and proceeds through glycolysis, pyruvate cannot cross into the TCA cycle when both signals are elevated. This is why the Randle Cycle’s fat-suppresses-glucose arm is most severe at the level of PDH rather than at glucose uptake or glycolysis. ^[4]

Regulation: PPAR-α, AMPK, and Transcriptional Control

Beta-oxidation is regulated at multiple timescales: acutely by substrate availability and the malonyl-CoA/CPT-1 gate (covered in the CPT-1 and Malonyl-CoA entities), and over longer timescales by transcriptional programmes driven by PPAR-α and AMPK. ^[2]

PPAR-α (peroxisome proliferator-activated receptor alpha) is the primary transcriptional regulator of mitochondrial and peroxisomal beta-oxidation gene expression. It upregulates CPT-1A, VLCAD, MCAD, and acyl-CoA oxidase (peroxisomal), and is activated by fatty acid ligands – particularly long-chain unsaturated fatty acids and their CoA esters – creating a feedforward system in which rising fatty acid availability drives transcription of the machinery to oxidise them. In fasting and high-fat dietary states, PPAR-α activation in liver, heart, and skeletal muscle is the molecular basis of the sustained upregulation of fat oxidation capacity. ^[2]

AMPK activates beta-oxidation acutely through the ACC/malonyl-CoA axis (phosphorylating and inactivating ACC, lowering malonyl-CoA, de-inhibiting CPT-1) and over longer timescales by activating PPAR-α coactivation pathways including PGC-1α, which drives mitochondrial biogenesis. An individual who exercises consistently for weeks develops greater beta-oxidation capacity not because individual enzyme molecules work faster but because there are more mitochondria – each containing the full complement of beta-oxidation enzymes and the complete electron transport chain. ^[2]

Beta-Oxidation in Skin

Beta-oxidation is not primarily a skin pathway – the skin’s major lipid metabolic activities involve synthesis ( ceramide elongation, cholesterol production, sebum generation) rather than fatty acid catabolism. However, it is relevant to skin biology in three specific contexts.

Keratinocyte differentiation and PPAR-α: PPAR-α, the transcriptional activator of beta-oxidation genes, is expressed in keratinocytes and directly influences epidermal differentiation and barrier formation. PPAR-α activators – including endogenous fatty acid ligands produced during differentiation and topical activators such as clofibrate at higher doses – enhance lamellar body formation, increase lipid secretion into the extracellular spaces of the stratum corneum, and upregulate differentiation markers including involucrin and transglutaminase-1. PPAR-α activation also has documented anti-inflammatory effects in keratinocytes, suppressing NF-κB signalling and reducing cytokine production. ^[7]

The practical implication is that PPAR-α ligands in topical formulations – including certain unsaturated fatty acids, niacinamide metabolites, and plant-derived terpenoids – engage the same receptor that drives beta-oxidation gene expression in metabolic tissues. Their benefit in skin is primarily through differentiation and anti-inflammatory effects rather than through activating fatty acid catabolism per se, but the receptor is shared and the downstream gene programmes partially overlap.

Wound healing and dermal fibroblasts: Dermal fibroblasts at rest rely substantially on fatty acid oxidation for their baseline energy needs, consistent with the cardiac and skeletal muscle pattern. During wound healing, infiltrating macrophages and proliferating keratinocytes shift toward glycolysis; resting fibroblasts in the wound periphery maintain beta-oxidation as their primary fuel pathway. The metabolic state of the client – specifically their beta-oxidation capacity – is therefore relevant to the tissue surrounding the wound as well as to the actively proliferating cells within it. ^[8]

Skin fibroblasts and peroxisomal VLCFA processing: The interdependence between mitochondrial and peroxisomal beta-oxidation documented in fibroblasts (above) means that impaired mitochondrial beta-oxidation from any cause – CPT-1 insufficiency, VLCAD deficiency, metabolic inflexibility constraining fat oxidation capacity – may also reduce peroxisomal VLCFA clearance in dermal fibroblasts. The clinical consequences in non-X-ALD contexts are not well-characterised; this is an emerging mechanistic connection rather than an established clinical finding.